A prodrug strategy to deliver cisplatin(IV) and paclitaxel in nanomicelles to improve efficacy and tolerance

Biomaterials

Volumn 33, Issue 27, 2012, Pages 6507-6519

  Xiao, Haihua ^a,b   Song, Haiqin ^c   Yang, Qiang ^d   Cai, Haidong ^e   Qi, Ruogu ^a,b   Yan, Lesan ^a,b   Liu, Shi ^a   Zheng, Yonghui ^a   Huang, Yubin ^a   Liu, Tongjun ^c   Jing, Xiabin ^a  

^a CHANGCHUN INSTITUTE OF APPLIED CHEMISTRY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c CHINA JAPAN UNION HOSPITAL OF JILIN UNIVERSITY   (China)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^e CHANGCHUN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Combination therapy; Drug delivery; Micelles; Paclitaxel; Platinum drugs

Indexed keywords

ACID HYDROLYSIS; AMPHIPHILIC BLOCK COPOLYMERS; ANTI-TUMOR EFFICACY; ANTICANCER DRUG; CANCEROUS CELLS; CIS-PLATIN; COMBINATION THERAPY; IN-VITRO; IN-VIVO; NANOMICELLES; PACLITAXEL; PLATINUM DRUGS; PRODRUGS; SYNERGISTIC EFFECT;

BLOCK COPOLYMERS; DRUG DELIVERY; MICELLES; PLATINUM;

PLATINUM COMPOUNDS;

ALANINE AMINOTRANSFERASE; AMPHOPHILE; ASPARTATE AMINOTRANSFERASE; CISPLATIN; CREATINE KINASE; CREATININE; GUANOSINE PHOSPHATE; LACTATE DEHYDROGENASE; PACLITAXEL; POLYMER;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CHELATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RELEASE; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG UPTAKE; HYDROPHOBICITY; IC 50; IN VITRO STUDY; IN VIVO STUDY; LACTATE DEHYDROGENASE BLOOD LEVEL; MICELLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; UREA NITROGEN BLOOD LEVEL; ZETA POTENTIAL;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DEATH; CELL LINE, TUMOR; CISPLATIN; DRUG DELIVERY SYSTEMS; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MICELLES; NANOPARTICLES; NEOPLASMS; PACLITAXEL; PARTICLE SIZE; POLYMERS; PRODRUGS; STATIC ELECTRICITY; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 84863565467     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.05.049     Document Type: Article

References (30)

1. Feldmann G., Dhara S., Fendrich V., Bedja D., Beaty R., Mullendore M., et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. Cancer Res 2007, 67:2187-2196.
2. Joensuu H., Holli K., Heikkinen M., Suonio E., Aro A.R., Hietanen P., et al. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol 1998, 16:3720-3730.
3. Woodcock J., Griffin J.P., Behrman R.E. Development of novel combination therapies. N Engl J Med 2011, 364:985-987.
4. Love R.R., Leventhal H., Easterling D.V., Nerenz D.R. Side effects and emotional distress during cancer-chemotherapy. Cancer 1989, 63:604-612.
5. Sitzia J., Huggins L. Side effects of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy for breast cancer. Cancer Pract 1998, 6:13-21.
6. Francesca G., Maria J.V. Combination therapy: Opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev 2009, 61:1203-1213.
7. Cohen S.M., Mukerji R., Cai S., Damjanov I., Forrest M.L. Subcutaneous delivery of nanoconjugated doxorubicin and cisplatin for locally advanced breast cancer demonstrates improved efficacy and decreased toxicity at lower doses than standard systemic combination therapy in vivo. Am J Surg 2011, 202:645-652.
8. Aryal S., Hu C.M.J., Zhang L.F. Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy. Mol Pharm 2011, 8:1401-1407.
9. Kolishetti N., Dhar S., Valencia P.M., Lin L.Q., Karnik R., Lippard S.J., et al. Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proc Natl Acad Sci USA 2010, 107:17939-17944.
10. Duncan R. The dawning era of polymer therapeutics. Nat RevDrug Discov 2003, 2:2347-2360.
11. Kwangjae C., Wang X., Nie S.M., Chen Z., Shin D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res 2008, 14:1310-1316.
12. Bae Y.H., Park K. Targeted drug delivery to tumors: Myths, reality and possibility. J Control Release 2011, 153:198-205.
13. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem 2010, 21:797-802.
14. Xiao H.H., Qi R.G., Liu S., Hu X.L., Lu T.C., Zheng Y.H., et al. Biodegradable polymer - cisplatin(IV) conjugate as a pro-drug of cisplatin(II). Biomaterials 2011, 32:7732-7739.
15. Deborah K.A., Brian B., Lari W., Helen Q.H., Rebecca B., Shashikant L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006, 354:34-43.
16. Rose P.G., Blessing J.A., Gershenson D.M., McGehee R. Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 1999, 17:2676-2680.
17. Moore K.N., Herzog T.J., Lewin S., Giuntoli R.L., Armstrong D.K., Rocconi R.P., et al. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol 2007, 105:299-303.
18. Xu X.Y., Zhang X.F., Wang X.H., Li Y.X., Jing X.B. Comparative study of paclitaxel physically encapsulated in and chemically conjugated with PEG-PLA. Polym Adv Technol 2009, 20:843-848.
19. Xiao H.H., Zhou D.F., Liu S., Zheng Y.H., Huang Y.B., Jing X.B. A complex of cyclohexane-1,2-diaminoplatinum with an amphiphilic biodegradable polymer with pendant carboxyl groups. Acta Biomaterial 1859, 2012:8-68.
20. Xie Z.G., Guang H.L., Chen L., Tian H.Y., Chen X.S., Jing X.B. Novel biodegradable poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-propylene carbonate) copolymers: Synthesis, characterization, and micellization. Polymer 2005, 46:10523-10530.
21. Xiao H.H., Zhou D.F., Liu S., Qi R.G., Zheng Y.H., Huang Y.B., et al. Delivery of active DACH-Pt anticancer species by biodegradable amphiphilic polymers using thiol-ene radical addition. Macromol Biosci 2011, 12:367-373.
22. Shahin M., Lavasanifar A. Novel self-associating poly(ethylene oxide)-b-poly(ε-caprolactone) based drug conjugates and nano-containers for paclitaxel delivery. Int J Pharm 2010, 389:213-222.
23. Hall M.D., Hambley T.W. Platinum(IV) antitumor compounds: their bioinorganic Chemistry. Coord Chem Rev 2002, 232:49-67.
24. Choi S., Filotto C., Bisanzo M., Delaney S., Lagasee D., Whitworth J.L., et al. Reduction and anticancer activity of platinum(IV) complexes. Inorg Chem 1998, 37:2500-2504.
25. Shi T.S., Berglund J., Elding L.I. Kinetics and mechanism for reduction of transdichlorotetracyanoplatinate(IV) by thioglycolic acid, l-cysteine, dlpenicillamine, and glutathione in aqueous solution. Inorg Chem 1996, 35:3498-3503.
26. Reiber H., Ruff M., Uhr M. Ascorbate concentration in human cerebrospinal fluid (CSF) and serum. Intrathecal accumulation and CSF flow rate. Clin Chim Acta 1993, 217:163-173.
27. Washko P., Rotrosen D., Levine M. Ascorbic acid in human neutrophils. Am J Clin Nutr 1991, 54:1221S-1227S.
28. Rowinsky E.K., Gilbert M.R., McGuire W.P., Noe D.A., Grochow L.B., Forastiere A.A., et al. Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 1991, 9:1692-1703.
29. Rowinsky E.K., Citardi M.J., Noe D.A., Donehower R.C. Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. J Cancer Res Clin 1993, 119:727-733.
30. Zhao L., Wientjes M.G., Au J.L.S., Zhao L., Wientjes M.G., Au J.L.S. Evaluation of combination chemotherapy integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 2004, 10:7994-8004.